CD34+ cell dose predicts costs after autologous peripheral blood stem cell transplantation for breast cancer.
We assessed the effect of CD34+ cell dose on costs in breast cancer patients undergoing autologous peripheral blood stem cell (PBSC) transplantation. Mean hospitalization costs were 26,992.9+/-9582.9 for patients receiving a CD34+ cell dose <5 x 10(6) cells/kg versus 22,339.4+/- 5471.1 for those receiving >5 x 10(6) CD34+ cells/kg (p=0.0065).
Baron
Frédéric
F
Copizza
Sandra
S
Baudoux
Etienne
E
Jerusalem
Guy
G
Fillet
Georges
G
Beguin
Yves
Y
D000328:Adult; D018952:Antigens, CD34 / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000191:economics* / Q000601:surgery; D002452:Cell Count; D003131:Combined Modality Therapy / Q000191:economics; D003365:Costs and Cost Analysis; D016527:Drug Costs; D005249:Fees and Charges; D005260:Female; D017721:Hospital Costs; D006801:Humans; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000191:economics*; D014182:Transplantation, Autologous / Q000191:economics
D018952:Antigens, CD34